The Annals Visit the PharmaCE website!
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 14 June 2005, www.theannals.com, DOI 10.1345/aph.1E589.
 The Annals of Pharmacotherapy: Vol. 39, No. 7, pp. 1194-1197. DOI 10.1345/aph.1E589
© 2005 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow For Our Patients
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Munier, A.
Right arrow Articles by Massy, Z.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Munier, A.
Right arrow Articles by Massy, Z.

ONCOLOGY

Zoledronic Acid and Renal Toxicity: Data from French Adverse Effect Reporting Database

Aline Munier

Pharmacy Resident, Service de Pharmacologie Clinique, Regional Pharmacovigilance Center, Amiens University Hospital (CHU) d'Amiens, Amiens, France

Valerie Gras, PharmD

Pharmacist, Service de Pharmacologie Clinique, Regional Pharmacovigilance Center, CHU d'Amiens

Michel Andrejak, MD

Professor, Head of Department, Service de Pharmacologie Clinique, Regional Pharmacovigilance Center, CHU d'Amiens

Nathalie Bernard, PharmD

Pharmacist, Regional Pharmacovigilance Center, CHU de Lyon, Lyon, France

Marie-Josephe Jean-Pastor, MD

Staff Physician, Regional Pharmacovigilance Center, CHU de Marseille, Marseille, France

Sophie Gautier, PharmD

Pharmacist, Regional Pharmacovigilance Center, CHU de Lille, Lille, France

Michel Biour, MD

Staff Physician, Regional Pharmacovigilance Center, University Hospital Saint Antoine, Paris, France

Ziad Massy, MD PhD

Professor, Services de Pharmacologie Clinique et de Néphrologie, CHU d'Amiens SUD

Reprints: Pr. Massy, Services de Pharmacologie Clinique et de Néphrologie, CHU d'Amiens SUD, Avenue René Laennec, 80054 Amiens Cedex 1, France, fax 33-3-22-45-57-60, massy{at}u-picardie.fr

BACKGROUND: Zoledronic acid–associated renal impairment leading to renal failure has been recently reported in a cohort of US patients. However, the presence of such toxicity in other populations has not yet been determined.

OBJECTIVE: To analyze French cases of zoledronic acid–associated nephrotoxicity.

METHODS: We evaluated available cases with acute deterioration of renal function associated with zoledronic acid therapy drawn from the French Adverse Event Reporting System database until July 1, 2004.

RESULTS: We identified 4 men and 3 women between the ages of 52 and 70 years, with multiple myeloma or different types of metastatic cancer, who had experienced renal impairment during zoledronic acid therapy. Four patients developed de novo acute renal failure, while the other 3 patients experienced acute deterioration of preexisting chronic renal failure. Renal failure occurred after various durations of zoledronic acid therapy (1–120 days). Three patients completely recovered and one partially recovered their previous renal function after discontinuation of zoledronic acid, but renal impairment was associated with a fatal outcome in 2 cases; the outcome of the other case was unknown. Our data confirm the previously reported risk factors for zoledronic acid–associated nephrotoxicity such as advanced cancer, multiple myeloma, preexisting renal failure, diabetes, hypertension, and concomitant use of nephrotoxic drugs.

CONCLUSIONS: These cases emphasize the need for regular monitoring of renal function during zoledronic acid treatment, with particular attention to patients with preexisting impaired renal function.

Key Words: zoledronic acid, bisphosphonates: nephrotoxicity, tubular necrosis

Published Online, June 14, 2005. www.theannals.com, DOI 10.1345/aph.1E589


This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
M. Bodmer, P. Amico, M. J. Mihatsch, M. Haschke, O. Kummer, S. Krahenbuhl, and M. Mayr
Focal segmental glomerulosclerosis associated with long-term treatment with zoledronate in a myeloma patient
Nephrol. Dial. Transplant., August 1, 2007; 22(8): 2366 - 2370.
[Full Text] [PDF]

Home page
 J Clin PharmacolHome page
R. Bergner, D. M. Henrich, M. Hoffmann, A. Honecker, G. Mikus, B. Nauth, D. Nagel, and M. Uppenkamp
Renal Safety and Pharmacokinetics of Ibandronate in Multiple Myeloma Patients With or Without Impaired Renal Function
J. Clin. Pharmacol., August 1, 2007; 47(8): 942 - 950.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. A. Kyle, G. C. Yee, M. R. Somerfield, P. J. Flynn, S. Halabi, S. Jagannath, R. Z. Orlowski, D. G. Roodman, P. Twilde, and K. Anderson
American Society of Clinical Oncology 2007 Clinical Practice Guideline Update on the Role of Bisphosphonates in Multiple Myeloma
J. Clin. Oncol., June 10, 2007; 25(17): 2464 - 2472.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
T. Tanvetyanon and P. J. Stiff
Management of the adverse effects associated with intravenous bisphosphonates
Ann. Onc., June 1, 2006; 17(6): 897 - 907.
[Abstract] [Full Text] [PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 2005 by Harvey Whitney Books Company.